An evaluation of the association between systemic inflammation – as measured by C-reactive protein – and hospital resource use

References

• Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest 2003;111:1805–12
   PubMed Web of Science ®Google Scholar
• Young B, Gleeson M, Cripps A. C-reactive protein: a critical review. Pathology 1991;23:118–24
   Google Scholar
• Kragsbjerg P, Holmberg H, Vikerfors T. Serum concentrations of interleukin-6, tumour necrosis factor and C-reactive protein in patients undergoing major operations. Eur J Surg 1995;161: 17–22
   Google Scholar
• Pepys MB, Baltz ML. Acute phase proteins with special reference to C-reactive protein and related proteins (pentraxins) and serum amyloid A protein. Adv Immunol 1983;34:141–211
   PubMed Web of Science ®Google Scholar
• Scirica BM, Morrow DA. Is C-reactive protein an innocent bystander or proatherogenic culprit? The verdict is still out. Circulation 2006;113:2128–34
   PubMed Web of Science ®Google Scholar
• Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. New Engl J Med 2002;347:1557–65
   PubMed Web of Science ®Google Scholar
• Pearson TA, Mensah GA, Alexander WR. Markers of inflammation and cardiovascular disease: application to clinical and public health practice a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499–511
   Google Scholar
• Shadick NA, Cook NR, Karlson EW, et al. C-reactive protein in the prediction of rheumatoid arthritis in women. Arch Intern Med 2006;166:2490–4
   PubMed Web of Science ®Google Scholar
• Kameda H, Sekiguchi N, Nagasawa H, et al. Development and validation of handy rheumatoid activity score with 38 joints (HRAS38) in rheumatoid arthritis patients receiving infliximab. Mod Rheumatol 2006;16:381–8
   PubMedGoogle Scholar
• Soubrier M, Zerkak D, Gossec L, et al. Which variables best predict change in rheumatoid arthritis therapy in daily clinical practice? J Rheumatol 2006;33:1243–6
   PubMed Web of Science ®Google Scholar
• Moreland LW, Weinblatt ME, Keystone EC, et al. Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience. J Rheumatol 2006;33:854–61
   PubMed Web of Science ®Google Scholar
• Dessein PH, Joffe BI, Singh S. Biomarkers of endothelial dysfunction, cardiovascular risk factors and atherosclerosis in rheumatoid arthritis. Arth Res Ther 2005;7:R634–R643
   Google Scholar
• Pahor A, Hojs R, Gorenjak M, Rozman B. Accelerated atherosclerosis in pre-menopausal female patients with rheumatoid arthritis. Rheumatol Int 2006;27:119–23
   PubMed Web of Science ®Google Scholar
• Georgiadis AN, Papavasiliou EC, Lourida ES, et al. Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: effect of early treatment – a prospective, controlled study. Arth Res Ther 2006;8:R82
   PubMed Web of Science ®Google Scholar
• Wakkee M, Thio HB, Prens EP, et al. Unfavorable cardiovascular risk profiles in untreated and treated psoriasis patients. Atherosclerosis 2007;190:1–9
   PubMed Web of Science ®Google Scholar
• Gelfand JM, Neimann AL, Shin DB, et al. Risk of myocardial infarction in patients with psoriasis. J Am Med Assoc 2006;296:1735–41
   PubMed Web of Science ®Google Scholar
• El Solh 1 A, Pinedal L, Bouquinl P, Mankowski C. Determinants of short and long term functional recovery after hospitalization for community-acquired pneumonia in the elderly: role of inflammatory markers. BMC Geriatrics 2006;6: 12
   PubMedGoogle Scholar
• Office of National Statistics. Census 2001: national report for England and Wales. London: The Stationary Office; 2003
   Google Scholar
• Currie CJ, Jones M, Goodfellow J, et al. Evaluation of survival and ischaemic and thromboembolic event rates in patients with non-valvar atrial fibrillation in the general population when treated and untreated with warfarin. Heart 2006;92:196–200
   PubMed Web of Science ®Google Scholar
• Currie CJ, Morgan CL, Peters JR. Patterns and costs of hospital care for coronary heart disease related and not related to diabetes. Heart 1997;78:544–9
   Google Scholar
• LinkageWiz Record Linkage Software. Available at: www. linkagewiz.com [last accessed 3 August 2007]
   Google Scholar
• Pearson TA, Mensah GA, Alexander WR. Markers of inflammation and cardiovascular disease: application to clinical and public health practice, a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499–511
   Google Scholar
• Miller M, Zhan M, Havas S. High attributable risk of elevated C-reactive protein level to conventional coronary heart disease risk factors: the Third National Health and Nutrition Examination Survey. Arch Intern Med 2005;165:2063–8
   Google Scholar
• NHS Executive. NHS performance indicators : July 2000. Technical specifications – readmission to hospital following discharge. Available from: www.performance.doh.gov.uk/nhsperformanceindicators/hlpi2000/c1139s.html [last accessed: 26 February 2007]
   Google Scholar
• Poole CD, Conway P, Currie CJ. An evaluation of the association between the first observation and the longitudinal change in C-reactive protein, and all-cause mortality. Heart 2007 [in press]
   Google Scholar